MONICA SAMUEL AVILA GRINBERG

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2021 × Tipo de acesso: restrictedAccess ×

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • conferenceObject
    Venous Thromboembolism as an Initial Manifestation of COVID-19 in a Heart Transplant Patient
    (2021) DANTAS, R. C. Tourinho; LIRA, M.; BELFORT, D.; ARAGAO, C.; MURAD, C.; AVILA, M.; SEGURO, L.; MANGINI, S.; CAMPOS, I.; MARCONDES-BRAGA, F.; BACAL, F.
  • conferenceObject
    Early Antibody-Mediated Rejection in Non-Pre-Sensitized Heart Transplant Recipient
    (2021) LIRA, M. S.; BELFORT, D. Sa Pereira; DANTAS, R. Cavalcanti Tourinho; ARAGAO, C. Aurelio Santos; AVILA, M. Samuel; SEGURO, L.; MANGINI, S.; CAMPOS, I. Wozniak; MARCONDES-BRAGA, F.; BACAL, F.
  • conferenceObject
    Prevalence of Cognitive Impairment in Heart Transplant Waiting List Patients in a Developing Country
    (2021) OLIVEIRA, F. M. de; IKEDA, E. T.; AVILA, M. S.; CAMPOS, I. W.; SEGURO, L. F.; SANTOS, M. V.; FELTRIM, M.; BARONE, F.; ISSA, V. S.; LAGE, S.; BOCCHI, E. A.; GAIOTTO, F. A.; NOMURA, C.; BACAL, F.; MARCONDES-BRAGA, F. G.; MANGINI, S.
  • conferenceObject
    Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease
    (2021) MARCONDES-BRAGA, F. G.; MURAD, C. M.; BELFORT, D. D.; DANTAS, R. C.; LIRA, M. S.; ARAGAO, C.; SICILIANO, R. F.; MANGINI, S.; SEGURO, L.; CAMPOS, I. W. de; AVILA, M. S.; BELLO, M. V.; BARONE, F.; STRABELLI, T. M.; GAIOTTO, F. A.; BACAL, F.
  • conferenceObject
    Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient
    (2021) BELFORT, D. S.; CAFEZEIRO, C. R.; FURLAN, D. A.; LIRA, M. S.; DANTAS, R. C.; ARAGAO, C. A.; CAMPOS, I. W.; AVILA, M. S.; MANGINI, S.; SEGURO, L. B.; MARCONDES-BRAGA, F. G.; BACAL, F.
  • conferenceObject
    Dermal Matrices Versatility
    (2021) SANCHES-PINTO, Debora C.; GOMEZ, David Souza; GEMPERLI, Rolf
  • conferenceObject
    Neurochagas: A Rare Case of Reactivation of Chagas Disease after Heart Transplantation
    (2021) ARAGAO, C. A.; CAMPOS, I. W.; DANTAS, R. T.; LIRA, M. T.; BELFORT, D. S.; MURAD, C. M.; AVILA, M. S.; SEGURO, L. F.; MANGINI, S.; STRABELLI, T. V.; BRAGA, F. M.; BACAL, F.
  • conferenceObject
    Reccurent Cardiac Myxoma Treated with Cardiac Transplantation: A Case Report
    (2021) MURAD, C. M.; BRAZ, J. C.; MOCKDECE, I. S.; OCAMPO, V. M.; MARCONDES-BRAGA, F. G.; CAMPO, I. W.; STEFFEN, S. P.; SEGURO, L. B.; MANGINI, S.; AVILA, M. S.; AIELLO, V. D.; GAIOTTO, F. A.; BACAL, F.
  • article 1 Citação(ões) na Scopus
    Transplantation for Chagas Heart Disease: a Comprehensive Review
    (2021) BACAL, Fernando; MURAD, Ciro Mancilha; ARAGAO, Carlos Aurelio dos Santos; CAMPOS, Iascara Wozniak de; SEGURO, Luis Fernando Bernal da Costa; AVILA, Monica Samuel; MANGINI, Sandrigo; GAIOTTO, Fabio Antonio; STRABELLI, Tania Varejao; MARCONDES-BRAGA, Fabiana G.
    Purpose of Review Chagas cardiomyopathy (CC) has a worse prognosis than other forms of cardiomyopathy and up to 10% of patients may progress to end-stage heart failure. In this article, we have performed a comprehensive literature review of heart transplantation (HT) for CC, including results after HT, management of immunosuppression, and Chagas disease (CD) reactivation. Recent Findings CD used to be considered a contraindication to HT due to the risks of disease reactivation with immunosuppression. Nonetheless, multiple reports have consistently demonstrated the feasibility and safety of HT for refractory CC. CD reactivation must be routinely screened in the first-year post-transplant, and in recent years, polymerase chain reactions (PCR)-based techniques have been used more often. HT is now considered the best treatment for end-stage Chagas heart disease. In addition, studies of immunosuppressive medications have shown that these patients require a lesser degree of immunosuppression, mainly to balance reactivation risks.
  • article 2 Citação(ões) na Scopus
    COVID-19 complicating perioperative management of LVAD implantation: A case report and systematic review
    (2021) BELFORT, Deborah de Sa Pereira; BISELLI, Bruno; AVILA, Monica Samuel; LIRA, Maria Tereza Sampaio de Sousa; GALAS, Filomena Regina Barbosa Gomes; STEFFEN, Samuel Padovani; GAIOTTO, Fabio Antonio; JATENE, Fabio Biscegli; BOCCHI, Edimar Alcides; FERREIRA, Silvia Moreira Ayub
    The coronavirus 2019 disease (COVID-19) affected 125 million people worldwide and caused 2.7 million deaths. Some comorbidities are associated with worse prognosis and left ventricular assist device (LVAD) recipients are probably part of this high-risk population. We report a 31-year-old male patient who developed COVID-19 during LVAD implantation. His postoperative period was complicated by severe pneumonia and mechanical ventilation (MV) leading to right ventricular failure (RVF) and inotrope necessity. He experienced multiple complications, but eventually recovered. We present a systematic review of LVAD recipients and COVID-19. Among 14 patients, the mean age was 62.7 years, 78.5% were male. A total of 5 patients (35.7%) required MV and 3 patients (21.4%) died. A total of 2 patients (14.2%) had thromboembolic events. This case and systematic review suggest LVAD recipients are at particular risk of unfavorable outcomes and they may be more susceptible to RVF in the setting of COVID-19, particularly during perioperative period.